TruScreen Ltd (NZAX:TRU) is pleased to confirm that its commercial capability in China has been expanded by its lead distributor (SWXT) with the addition of the BioChem Group (China Health Labs & Diagnostics Ltd) as a sub distributor.
BioChem has expertise in distribution of medical products and services into Chinese government programs and will focus on the delivery of TruScreen products to the thousands of county and village level healthcare centres throughout China.
BioChem Group which has its head office located in Beijing has over 400 employees and in excess of
1000 healthcare centres in 13 provinces.
BioChem’s founder and Chairman, Mr Yao Shiping, confirmed that they are working with the Women’s and Children’s Healthcare Division of the Centre for Disease Control (CDC) in China to cooperate in the evaluation of TruScreen. The evaluation has the goal of having the CDC recommend TruScreen for use in major central government screening programs and to be included in the list of basic medical equipment for the over 30,000 community healthcare centres throughout China.
TruScreen Chairman Robert Hunter said “China is a primary target market and BioChem will add significantly to our distribution capabilities within China.”
TruScreen Chief Executive Officer
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.